来源：生物谷 2013-07-30 22:34
2013年7月30日讯 /生物谷BIOON/ --Celgene公司与Array公司达成了一项价值1100万美元的协议，在抗炎症领域中结成合作伙伴关系，合作研究揭示炎症的成因。Celgene公司近年来已经和很多企业合作在炎症领域进行深入研究，这次的协议只是其中之一。但双方并未透露合约中涉及的新药的研究情况和机理。（生物谷Bioon.com）
详细英文报道：
Array BioPharma ($ARRY) has pocketed $11 million from Celgene for a preclinical-stage partnership to discover drugs against an undisclosed cause of inflammation. The heavily back-ended payment schedule for the deal includes up to $376 million in payments from Celgene ($CELG) based on the success of drug candidates from Array, which also stands to gain royalty checks on potential winners.
Celgene has spread its bets widely across a number of external groups working on discovering drugs for inflammation and cancer. And the arrangement with Array represents a relatively small upfront bet for the Summit, NJ-based biotech powerhouse, which has just forked over $100 million for an option to buy Acetylon and the Boston startup's HDAC6 inhibitor in early clinical development for myeloma.
Array is also active on the partnership scene and has relied on collaborators such as Roche ($RHHBY) and Novartis ($NVS) to advance some of its leading drug candidates in oncology. The company also just revealed upbeat midstage data in asthma patients for an oral CRTh2 antagonist called ARRY-502, which could be one of the Boulder, CO-based developer's next assets for a partnership. That is the company's hope.
Celgene and Array did not disclose the details of the inflammation pathway involved in their new collaboration. Yet clinical trials have validated Array's ability to discover small-molecule compounds with activity against causes of inflammation and pain.
"Given Celgene's global leadership and expertise in the development and commercialization of innovative therapies and Array's solid track record of inventing and progressing targeted drugs into clinical trials," Array Chief Scientific Officer Kevin Koch stated, "we believe this alliance will maximize the value of a very exciting and innovative program."
Array has the right to take over development of any compounds from the alliance that Celgene opts not to pursue. Shares of Array jumped 7% to $6.70 per share in after-hours trading Monday.
EMBO Mol Med：鉴别出慢性炎症性结肠癌的新型治疗靶点
APP专享
Cell：肠道免疫细胞能够抑制多发性硬化引发的炎症反应
APP专享
Cell Metabol：炎性受体或会介导脂质诱导的机体炎症反应
APP专享
祝贺！天境生物首个自主新药TJM2获美国FDA颁发临床试验批件，治疗自身免疫/炎症疾病
APP专享
Nature：重大进展！鉴定出治疗动脉粥样硬化和炎症性疾病的新药物靶标---一组SLC基因
APP专享
Nature：一个新鉴定出的Th17细胞亚群或是抵抗慢性炎症性疾病的关键
APP专享
吃零食会让机体长期处于低度炎症状态进而影响全身健康
APP专享
罗氏抗炎症新药达到3期主要终点 获突破性疗法认定
APP专享
吴开春教授丨如何看待干细胞移植和粪菌移植治疗炎症性肠病
APP专享
Celgene和bluebird共同宣布：针对多发性骨髓瘤的BCMA CAR-T进入二期临床试验
APP专享
空中讲坛 Webinar
